ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years
Bo Zhang
Matched on ORCID iD 0000-0002-2808-2242; OpenAlex author ID A5040980002. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 14
2022: 1 paper · 2023: none · 2024: 2 papers · 2025: 1 paper
Papers 4
- Global burden of early-onset pancreatic cancer attributable to metabolic risks from 1990 to 2021, and projections to 2030. Last author DOI 10.3389/fonc.2025.1660313↗
- Construction of a Novel Disulfidptosis-Related lncRNA Prognostic Signature in Pancreatic Cancer. Last author DOI 10.1007/s12033-023-00875-z↗
- CircRREB1 Mediates Metabolic Reprogramming and Stemness Maintenance to Facilitate Pancreatic Ductal Adenocarcinoma Progression. Co-author DOI 10.1158/0008-5472.can-23-3596↗
- The Role of PDGFRA in Predicting Oncological and Immune Characteristics in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1155/2022/4148805↗
Closest collaborators
The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jin Xu · 3 shared papers, 2022–2024 · strength 0.63
- Paper Construction of a Novel Disulfidptosis-Related lncRNA Prognostic Signature in Pancreatic Cancer. DOI 10.1007/s12033-023-00875-z↗
- Paper CircRREB1 Mediates Metabolic Reprogramming and Stemness Maintenance to Facilitate Pancreatic Ductal Adenocarcinoma Prog… DOI 10.1158/0008-5472.can-23-3596↗
- Paper The Role of PDGFRA in Predicting Oncological and Immune Characteristics in Pancreatic Ductal Adenocarcinoma. DOI 10.1155/2022/4148805↗
- Xianjun Yu · 3 shared papers, 2022–2025 · strength 0.58
- Paper Global burden of early-onset pancreatic cancer attributable to metabolic risks from 1990 to 2021, and projections to 20… DOI 10.3389/fonc.2025.1660313↗
- Paper CircRREB1 Mediates Metabolic Reprogramming and Stemness Maintenance to Facilitate Pancreatic Ductal Adenocarcinoma Prog… DOI 10.1158/0008-5472.can-23-3596↗
- Paper The Role of PDGFRA in Predicting Oncological and Immune Characteristics in Pancreatic Ductal Adenocarcinoma. DOI 10.1155/2022/4148805↗
- Faliang Xing · 2 shared papers, 2024–2025 · strength 0.51
- Qingcai Meng · 2 shared papers, 2024–2025 · strength 0.41
- Paper Global burden of early-onset pancreatic cancer attributable to metabolic risks from 1990 to 2021, and projections to 20… DOI 10.3389/fonc.2025.1660313↗
- Paper CircRREB1 Mediates Metabolic Reprogramming and Stemness Maintenance to Facilitate Pancreatic Ductal Adenocarcinoma Prog… DOI 10.1158/0008-5472.can-23-3596↗
- Chen Liang · 2 shared papers, 2024–2025 · strength 0.41
- Paper Global burden of early-onset pancreatic cancer attributable to metabolic risks from 1990 to 2021, and projections to 20… DOI 10.3389/fonc.2025.1660313↗
- Paper CircRREB1 Mediates Metabolic Reprogramming and Stemness Maintenance to Facilitate Pancreatic Ductal Adenocarcinoma Prog… DOI 10.1158/0008-5472.can-23-3596↗
- Rong Tang · 2 shared papers, 2022–2024 · strength 0.35
- Paper CircRREB1 Mediates Metabolic Reprogramming and Stemness Maintenance to Facilitate Pancreatic Ductal Adenocarcinoma Prog… DOI 10.1158/0008-5472.can-23-3596↗
- Paper The Role of PDGFRA in Predicting Oncological and Immune Characteristics in Pancreatic Ductal Adenocarcinoma. DOI 10.1155/2022/4148805↗
- Si Shi · 2 shared papers, 2022–2024 · strength 0.35
- Paper CircRREB1 Mediates Metabolic Reprogramming and Stemness Maintenance to Facilitate Pancreatic Ductal Adenocarcinoma Prog… DOI 10.1158/0008-5472.can-23-3596↗
- Paper The Role of PDGFRA in Predicting Oncological and Immune Characteristics in Pancreatic Ductal Adenocarcinoma. DOI 10.1155/2022/4148805↗
- Wei Wang · 1 shared paper, 2024 · strength 0.28
- Yi Qin · 1 shared paper, 2024 · strength 0.28
- Yingjin Fang · 1 shared paper, 2025 · strength 0.23
- Jie Hua · 1 shared paper, 2024 · strength 0.18
- Zhen Tan · 1 shared paper, 2024 · strength 0.18
- Zeyin Rong · 1 shared paper, 2024 · strength 0.18
- Zijian Wu · 1 shared paper, 2022 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.